Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end1 Over 60% of...
-
Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union1New seven-year data from the LADDER study...
-
Dublin, Sept. 01, 2025 (GLOBE NEWSWIRE) -- The "Automotive AI Market by Offerings (Compute, Memory, Software), Level of Autonomy (L1, L2, L3, L4, L5), Technology (Deep Learning, ML, Computer Vision,...
-
Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Implants Market - Focused Insights 2025-2030" has been added to ResearchAndMarkets.com's offering.The Ophthalmic Implants Market was valued...
-
Chicago, July 08, 2025 (GLOBE NEWSWIRE) -- As consumer interest in non-prescription eye health continues to surge in 2025, search trends reveal a sharp uptick in queries for the best clean label...
-
Pune, July 03, 2025 (GLOBE NEWSWIRE) -- Generative AI in Logistics Market Size Analysis: “The Generative AI in Logistics Market is projected to grow significantly, expanding from USD 816.15 million...
-
Facilities and care team tailored for patients with complex medical needs Specialized protocol includes optimized dosing and therapeutic support for patients with conditions like Parkinson's and...
-
Chicago, June 02, 2025 (GLOBE NEWSWIRE) -- The global automotive radar market was valued at US$ 6.93 billion in 2024 and is expected to reach US$ 43.49 billion by 2033, growing at a CAGR of 25.20%...
-
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of...
-
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine monthsSusvimo’s innovative technology via the Port...